Immunome (NASDAQ:IMNM) Given “Overweight” Rating at Stephens

Immunome (NASDAQ:IMNM)‘s stock had its “overweight” rating reiterated by equities researchers at Stephens in a research note issued to investors on Thursday,Benzinga reports. They currently have a $30.00 price target on the stock. Stephens’ price target points to a potential upside of 250.39% from the company’s current price.

Several other equities research analysts have also recently issued reports on IMNM. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Monday, March 10th. Guggenheim decreased their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, Lifesci Capital started coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $25.50.

Immunome Stock Down 0.1 %

NASDAQ:IMNM opened at $8.56 on Thursday. Immunome has a 52 week low of $8.30 and a 52 week high of $26.70. The stock has a market capitalization of $683.05 million, a PE ratio of -1.06 and a beta of 1.93. The stock’s 50-day moving average price is $9.84 and its 200-day moving average price is $11.64.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. Sell-side analysts expect that Immunome will post -2.21 earnings per share for the current fiscal year.

Insider Activity

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the company’s stock in a transaction on Friday, January 31st. The stock was acquired at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the completion of the purchase, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several institutional investors have recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in shares of Immunome by 6.6% during the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after purchasing an additional 1,520 shares in the last quarter. Sequoia Financial Advisors LLC grew its stake in shares of Immunome by 11.7% during the fourth quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock worth $202,000 after purchasing an additional 2,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Immunome by 5.1% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock worth $441,000 after purchasing an additional 2,005 shares in the last quarter. Intech Investment Management LLC grew its stake in shares of Immunome by 26.5% during the fourth quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock worth $201,000 after purchasing an additional 3,974 shares in the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Immunome by 3.5% during the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after purchasing an additional 4,874 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.